Route of Administration:
FULVESTRANT is a Cancer drug manufactured by Teva and administered via the Intramuscular route of administration. The J Code: J9393 is aligned to the drug FULVESTRANT.
Fulvestrant is an estrogen receptor antagonist which binds to the receptor in breast cancer cells for the hormone estrogen. After binding to these breast cancer cells, it eventually degrades them. This medication is administered via injection into the muscle. Patient assistance can be found through Astrazeneca Pharmaceuticals through the AZ & Me prescription savings program here: https://www.azandmeapp.com/prescriptionsavings/ or their personal support program here: https://www.myaccess360.com/faslodex-fulvestrant.html. Additionally, Fresenius Kabi offers a patient support site here: https://kabicare.us/patient/.